Cingulate Names Nilay Patel Chief Legal Officer, Prepares ADHD Drug Filing

Posted July 16, 2025

Cingulate has named Nilay Patel as its chief legal officer weeks ahead of when the company plans to submit its new drug application to the FDA.

Patel brings over two decades of experience in legal and compliance leadership within the pharmaceutical industry, according to a release. He most recently served as a chief legal officer, chief compliance officer and corporate secretary at Ironshore Pharmaceuticals. While at Ironshore, Patel helped with the commercial launch of an ADHD treatment project.

He also held senior legal roles at Grifols for eight years, where he served in the company’s U.S. Bioscience division as its assistant general counsel, according to his LinkedIn profile. Before that, Patel worked at Life Sciences Law PLLC for five years, where he represented both emerging biotech firms and global pharmaceutical clients in licensing, mergers and acquisitions, and intellectual property matters.

“I’m honored to join Cingulate at an exciting and inflectional stage in its growth,” Patel said in the release. “I was drawn to Cingulate because of its seasoned management team and innovative approach to addressing long-standing challenges in ADHD treatment through science-driven, patient-focused solutions, and I look forward to advancing the company’s vision and long-term success as we move closer to commercialization.”

Cingulate is preparing to submit an FDA application for its new ADHD treatment drug, dubbed CTx-1301. The drug is a precision time-released technology that would allow for a once-daily dose as opposed to other multi-dose ADHD medications.

Another drug is being worked on at Cingulate, which is a similar once-daily treatment for anxiety and anxiety-related disorders. The anxiety treatment received a $3 million grant in April to help accelerate its development.